An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Pravastatin, Diltiazem, Naproxen Sodium and Meloxicam in API, Pharmaceutical Formulations and Human Serum

Najma Sultana; Muhammad Saeed Arayne; Saeeda Nadir Ali

doi:doi:10.11648/j.ajac.20130101.11

| Peer-Reviewed

An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Pravastatin, Diltiazem, Naproxen Sodium and Meloxicam in API, Pharmaceutical Formulations and Human Serum

Najma Sultana, Muhammad Saeed Arayne, Saeeda Nadir Ali

Published in American Journal of Applied Chemistry (Volume 1, Issue 1)

Published: 2 April 2013

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

The aim of the present work was to develop a sensitive liquid chromatographic method for the quantitation of pravastatin and diltiazem along with naproxen and meloxicam using ultraviolet detector. The separation of components was achieved on Purospher Star, C18 (5 µm, 25 x 0.46 cm) column using methanol-water (80:20 v/v) as mobile phase and pH adjusted 3.4 with 85% o-phosphoric acid. Related parameters that may influence the enrichment efficiency of speration of drugs such as the kind and volume of elute, sample flow rate, sample pH, and volume of the drug samples were investi-gated. Detection was performed at ambient temperature at 220 nm by pumping the mobile phase at the flow rate 1.0 mL min-1. The experimental results indicated a good linearity (R 2 > 0.9947) over the concentration range of 0.5-20 µg mL-1 for pravastatin, naproxen and meloxicam and 0.75-24 µg mL-1 for diltiazem. The method was compared by programming the detector adjusting the wavelength with time to match the individual analyte's chromophore which enhanced sensitivity with linear range 0.25-8.0, 0.5-16, 0.4-12 and 0.2-4.0 µg mL-1 for pravastatin, diltiazem, naproxen and meloxicam respectively. The LOD values shifted down from 33, 70, 50 and 80 ng mL-1 to 15, 42, 20 and 10 ng mL-1 for pravastatin, diltiazem, na-proxen and meloxicam respectively. Validation of the method showed good precision and accuracy for the proposed method. All the results indicated that this procedure could allow the simultaneous determination of these four compounds in API, pharmaceutical formulations and serum at trace levels. The method can be successfully applied for the determination of these drugs in human serum, clinical laboratories and in pharmaceutical formulations without diode array detector and without interference of excipients or endogenous components of serum.

Published in	American Journal of Applied Chemistry (Volume 1, Issue 1)
DOI	10.11648/j.ajac.20130101.11
Page(s)	1-8
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2013. Published by Science Publishing Group

Keywords

Pravastatin, Diltiazem, Naproxen, Meloxicam, RP-HPLC, Time Program

References

[1]	Y. An, H. Xin, W. Yan, X. Zhou, Exp. Toxicol. Pathol. 2011, 63, 215.
[2]	G. Mariucci, E. Taha, M. Tantucci, C. Spaccatini, A. Tozzi, M. V. Ambrosini, Eur. J. Pharmacol. 2011, 660, 381.
[3]	J. D. Dietz, S. Du, C. W. Bolten, M. A. Payne, C. Xia, J.R. Blinn, J.W. Funder, X. Hu, Hypertension 2008, 51, 742.
[4]	V. Andrisano, P. Hrelia, R. Gotti, A. Leoni, V. Cavrini, J. Pharm. Biomed. Anal. 2001, 25, 589.
[5]	L. G Lala, P. M. D'Mello, S. R. Naik, J. Pharm. Biomed. Anal. 2002, 29, 539.
[6]	A. G. Gnidec, W. J. Sibbald, H. Cheung, C.A. Metz, J. Appl. Physiol. 1988, 65, 1024.
[7]	N. K. S. Khoo, F. P. H. Chan, M. N. Saarloos, P. K. Lala, Clin. Exp. Metastasis. 1992, 10, 239.
[8]	T. P Kennedy, N. V Rao, W. Noah, J. R. Michael, J. M. H. Jafri, G. H. Gurtner, J. R. Hoidal, J. Clin. Invest. 1990, 86, 1565.
[9]	K. Kircali, M. Tuncel, H. Y. Aboul-Enein, IL Farmaco. 2004, 59, 241.
[10]	S. Ashour, H. Nakshbandi, S. Omar, Int. J. Biomed. Sci. 2008, 4, 135.
[11]	K. Cai, B. Tan, Z. Feng, Z. Li, M. Huang, X. Zhao, Chin. J. Chromatogr. 1996, 14, 121.
[12]	B. G. Chaudhari, N. M. Patel, P. B. Shah, Indian. J. Pharm. Sci. 2007, 69, 130.
[13]	I. A. Darwish, A. R. M. Al-Obaid, H. A. Al-Malaq, Talanta. 2009, 79, 1478.
[14]	M. M. Ayad, A. Shalaby, H. E. Abdellatef, M. M. Hosny, Anal. Bioanal. Chem. 2003, 376, 710.
[15]	R. I. L. Catarino, A. C. L. Conceição, M. B. Q. Garcia, M. L. S. Goncalves, J. L. F. C. Lima, M. M. Correia dos Santos, J. Pharm. Biomed. Anal. 2003, 33, 571.
[16]	N. Sultana, M.S. Arayne, N. Shafi, Pak. J. Pharm. Sci. 2007, 20, 279.
[17]	P. V. Devarajan, V. V. Dhavse, J. Chromatogr. B: Biomed. Appl. 1998, 706, 362.
[18]	O. Grech-Belanger, E. Leboeuf, S. Langlois, J. Chromatogr. B: Biomed. Appl. 1987, 417, 89.
[19]	M. A. Sanchez, F. R. P. Rocha, Anal. Chim. Acta. 2011, 694, 95.
[20]	T. M. Phillips, E. F. Wellner, Biomed. Chromatogr. 2006, 20, 662.
[21]	A. Aresta, F. Palmisano, C. G. Zambonin, J. Pharm. Biomed. Anal. 2005, 39, 643.
[22]	M. H. Guermouche, N. Atik, H. Chader, J. AOAC Int. 2002, 83, 1489.
[23]	I. R. Miksa, M. R. Cummings, R. H. Poppenga, J. Anal. Toxicol. 2005, 29, 95.
[24]	N. E. Larsen, K. Marinelli, J. Chromatogr. B: Biomed. Appl. 1981, 222, 482.
[25]	E. A. Taha, N. N. Salama, L. E. S. A. Fattah, Chem. Pharm. Bull. 1981, 54, 653.
[26]	A. E. Radi, M. Ghoneim, A. Beltagi, Chem. Pharm. Bull. 2001, 49, 1257.
[27]	E. M. Hassan, J. Pharm. Biomed. Anal. 2002, 27, 771.
[28]	W. R. G. Baeyens, G. Van der Weken, E. D’haeninck, A. M. Garcia-Campana, T. Vankeirsbilck, A. Vercauteren, P. Deprez, J. Pharm. Biomed. Anal. 2003, 32, 839.
[29]	S. E. Vignaduzzo, P. M. Castellano, T. S. Kaufman, J. Pharm. Biomed. Anal. 2008, 46, 219.
[30]	Y. H. Hsieh, S. J. Lin, S. H. Chen, J. Sep. Sci. 2006, 29, 1009.
[31]	N. Sultana, M. S. Arayne, S. N. Ali, M. H. Zuberi, Med. Chem. Res. 2012, 21, 2443.
[32]	M. S. Arayne, N. Sultana, A. Tabassum, S. N. Ali, S. Naveed, Med. Chem. Res. 2012, 21, 4542.
[33]	M. S. Arayne, N. Sultana, S. N. Ali, Amer. J. Anal. Chem. 2013, 4, 24.
[34]	N. Sultana, M. S. Arayne, W. Shahzad, J. Chil. Chem. Soc. 2010, 55, 193.
[35]	N. Sultana, M. S. Arayne, N. Safila, Chin. J. Chem. 2011, 29, 1216.
[36]	N. Sultana, M. S. Arayne, R. Siddique, N. Safila, Amer. J. Anal. Chem. 2012, 3, 147.
[37]	N. Sultana, M. S. Arayne, S. N. Ali, Anal. Bioanal. Techniques. 2013, 3, 154.
[38]	M. S. Arayne, N. Sultana, A. Tabassum, Res. Rep. Med. Chem. 2012, 2, 19.
[39]	N. Sultana, M. S. Arayne, N. Safila, F. A. Siddiqui, Chromatographia. 2010, 71, 71.
[40]	M. S. Arayne, N. Sultana, F. A. Siddiqui, Pak. J. Pharm. Sci. 2005, 18, 58.
[41]	N. Sultana, M. S. Arayne, B. Iftikhar, J. Chin. Chem. Soc. 2008, 5, 1022.
[42]	International Conference of Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedure: Text and Methodology Q2 (R1) Complimentary Guideline on Methodology Dated 06 Nov 1996, Incorporated in Nov 2005, London.
[43]	D. A. Armbruster, M. D. Tillman, L. M. Hubbs, Clin. J. Chem. 1994, 40, 1233.

Cite This Article

Plain Text BibTeX RIS

APA Style

Najma Sultana, Muhammad Saeed Arayne, Saeeda Nadir Ali. (2013). An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Pravastatin, Diltiazem, Naproxen Sodium and Meloxicam in API, Pharmaceutical Formulations and Human Serum. American Journal of Applied Chemistry, 1(1), 1-8. https://doi.org/10.11648/j.ajac.20130101.11

Copy | Download

ACS Style

Najma Sultana; Muhammad Saeed Arayne; Saeeda Nadir Ali. An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Pravastatin, Diltiazem, Naproxen Sodium and Meloxicam in API, Pharmaceutical Formulations and Human Serum. Am. J. Appl. Chem. 2013, 1(1), 1-8. doi: 10.11648/j.ajac.20130101.11

Copy | Download

AMA Style

Najma Sultana, Muhammad Saeed Arayne, Saeeda Nadir Ali. An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Pravastatin, Diltiazem, Naproxen Sodium and Meloxicam in API, Pharmaceutical Formulations and Human Serum. Am J Appl Chem. 2013;1(1):1-8. doi: 10.11648/j.ajac.20130101.11

Copy | Download

@article{10.11648/j.ajac.20130101.11,
  author = {Najma Sultana and Muhammad Saeed Arayne and Saeeda Nadir Ali},
  title = {An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Pravastatin, Diltiazem, Naproxen Sodium and Meloxicam in API, Pharmaceutical Formulations and Human Serum},
  journal = {American Journal of Applied Chemistry},
  volume = {1},
  number = {1},
  pages = {1-8},
  doi = {10.11648/j.ajac.20130101.11},
  url = {https://doi.org/10.11648/j.ajac.20130101.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajac.20130101.11},
  abstract = {The aim of the present work was to develop a sensitive liquid chromatographic method for the quantitation of pravastatin and diltiazem along with naproxen and meloxicam using ultraviolet detector. The separation of components was achieved on Purospher Star, C18 (5 µm, 25 x 0.46 cm) column using methanol-water (80:20 v/v) as mobile phase and pH adjusted 3.4 with 85% o-phosphoric acid. Related parameters that may influence the enrichment efficiency of speration of drugs  such as the kind and volume of elute, sample flow rate, sample pH, and volume of the drug  samples were investi-gated. Detection was performed at ambient temperature at 220 nm by pumping the mobile phase at the flow rate 1.0 mL min-1. The experimental results indicated a good linearity (R 2 > 0.9947) over the concentration range of 0.5-20 µg mL-1 for pravastatin, naproxen and meloxicam and 0.75-24 µg mL-1 for diltiazem. The method was compared by programming the detector adjusting the wavelength with time to match the individual analyte's chromophore which enhanced sensitivity with linear range 0.25-8.0, 0.5-16, 0.4-12 and 0.2-4.0 µg mL-1 for pravastatin, diltiazem, naproxen and meloxicam respectively. The LOD values shifted down from 33, 70, 50 and 80 ng mL-1 to 15, 42, 20 and 10 ng mL-1 for pravastatin, diltiazem, na-proxen and meloxicam respectively. Validation of the method showed good precision and accuracy for the proposed method. All the results indicated that this procedure could allow the simultaneous determination of these four compounds in API, pharmaceutical formulations and serum at trace levels. The method can be successfully applied for the determination of these drugs in human serum, clinical laboratories and in pharmaceutical formulations without diode array detector and without interference of excipients or endogenous components of serum.},
 year = {2013}
}

Copy | Download

TY  - JOUR
T1  - An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Pravastatin, Diltiazem, Naproxen Sodium and Meloxicam in API, Pharmaceutical Formulations and Human Serum
AU  - Najma Sultana
AU  - Muhammad Saeed Arayne
AU  - Saeeda Nadir Ali
Y1  - 2013/04/02
PY  - 2013
N1  - https://doi.org/10.11648/j.ajac.20130101.11
DO  - 10.11648/j.ajac.20130101.11
T2  - American Journal of Applied Chemistry
JF  - American Journal of Applied Chemistry
JO  - American Journal of Applied Chemistry
SP  - 1
EP  - 8
PB  - Science Publishing Group
SN  - 2330-8745
UR  - https://doi.org/10.11648/j.ajac.20130101.11
AB  - The aim of the present work was to develop a sensitive liquid chromatographic method for the quantitation of pravastatin and diltiazem along with naproxen and meloxicam using ultraviolet detector. The separation of components was achieved on Purospher Star, C18 (5 µm, 25 x 0.46 cm) column using methanol-water (80:20 v/v) as mobile phase and pH adjusted 3.4 with 85% o-phosphoric acid. Related parameters that may influence the enrichment efficiency of speration of drugs  such as the kind and volume of elute, sample flow rate, sample pH, and volume of the drug  samples were investi-gated. Detection was performed at ambient temperature at 220 nm by pumping the mobile phase at the flow rate 1.0 mL min-1. The experimental results indicated a good linearity (R 2 > 0.9947) over the concentration range of 0.5-20 µg mL-1 for pravastatin, naproxen and meloxicam and 0.75-24 µg mL-1 for diltiazem. The method was compared by programming the detector adjusting the wavelength with time to match the individual analyte's chromophore which enhanced sensitivity with linear range 0.25-8.0, 0.5-16, 0.4-12 and 0.2-4.0 µg mL-1 for pravastatin, diltiazem, naproxen and meloxicam respectively. The LOD values shifted down from 33, 70, 50 and 80 ng mL-1 to 15, 42, 20 and 10 ng mL-1 for pravastatin, diltiazem, na-proxen and meloxicam respectively. Validation of the method showed good precision and accuracy for the proposed method. All the results indicated that this procedure could allow the simultaneous determination of these four compounds in API, pharmaceutical formulations and serum at trace levels. The method can be successfully applied for the determination of these drugs in human serum, clinical laboratories and in pharmaceutical formulations without diode array detector and without interference of excipients or endogenous components of serum.
VL  - 1
IS  - 1
ER  -

Copy | Download

Author Information

Najma Sultana

Department of Pharmaceutical Chemistry, University of Karachi, Karachi-75270, Pakistan
Muhammad Saeed Arayne

Department of Chemistry, University of Karachi, Karachi-75270, Pakistan
Saeeda Nadir Ali

Department of Chemistry, University of Karachi, Karachi-75270, Pakistan

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Najma Sultana, Muhammad Saeed Arayne, Saeeda Nadir Ali. (2013). An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Pravastatin, Diltiazem, Naproxen Sodium and Meloxicam in API, Pharmaceutical Formulations and Human Serum. American Journal of Applied Chemistry, 1(1), 1-8. https://doi.org/10.11648/j.ajac.20130101.11

Copy | Download

ACS Style

Najma Sultana; Muhammad Saeed Arayne; Saeeda Nadir Ali. An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Pravastatin, Diltiazem, Naproxen Sodium and Meloxicam in API, Pharmaceutical Formulations and Human Serum. Am. J. Appl. Chem. 2013, 1(1), 1-8. doi: 10.11648/j.ajac.20130101.11

Copy | Download

AMA Style

Najma Sultana, Muhammad Saeed Arayne, Saeeda Nadir Ali. An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Pravastatin, Diltiazem, Naproxen Sodium and Meloxicam in API, Pharmaceutical Formulations and Human Serum. Am J Appl Chem. 2013;1(1):1-8. doi: 10.11648/j.ajac.20130101.11

Copy | Download

@article{10.11648/j.ajac.20130101.11,
  author = {Najma Sultana and Muhammad Saeed Arayne and Saeeda Nadir Ali},
  title = {An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Pravastatin, Diltiazem, Naproxen Sodium and Meloxicam in API, Pharmaceutical Formulations and Human Serum},
  journal = {American Journal of Applied Chemistry},
  volume = {1},
  number = {1},
  pages = {1-8},
  doi = {10.11648/j.ajac.20130101.11},
  url = {https://doi.org/10.11648/j.ajac.20130101.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajac.20130101.11},
  abstract = {The aim of the present work was to develop a sensitive liquid chromatographic method for the quantitation of pravastatin and diltiazem along with naproxen and meloxicam using ultraviolet detector. The separation of components was achieved on Purospher Star, C18 (5 µm, 25 x 0.46 cm) column using methanol-water (80:20 v/v) as mobile phase and pH adjusted 3.4 with 85% o-phosphoric acid. Related parameters that may influence the enrichment efficiency of speration of drugs  such as the kind and volume of elute, sample flow rate, sample pH, and volume of the drug  samples were investi-gated. Detection was performed at ambient temperature at 220 nm by pumping the mobile phase at the flow rate 1.0 mL min-1. The experimental results indicated a good linearity (R 2 > 0.9947) over the concentration range of 0.5-20 µg mL-1 for pravastatin, naproxen and meloxicam and 0.75-24 µg mL-1 for diltiazem. The method was compared by programming the detector adjusting the wavelength with time to match the individual analyte's chromophore which enhanced sensitivity with linear range 0.25-8.0, 0.5-16, 0.4-12 and 0.2-4.0 µg mL-1 for pravastatin, diltiazem, naproxen and meloxicam respectively. The LOD values shifted down from 33, 70, 50 and 80 ng mL-1 to 15, 42, 20 and 10 ng mL-1 for pravastatin, diltiazem, na-proxen and meloxicam respectively. Validation of the method showed good precision and accuracy for the proposed method. All the results indicated that this procedure could allow the simultaneous determination of these four compounds in API, pharmaceutical formulations and serum at trace levels. The method can be successfully applied for the determination of these drugs in human serum, clinical laboratories and in pharmaceutical formulations without diode array detector and without interference of excipients or endogenous components of serum.},
 year = {2013}
}

Copy | Download

TY  - JOUR
T1  - An Ultra-Sensitive and Selective LC-UV Method for the Simultaneous Determination of Pravastatin, Diltiazem, Naproxen Sodium and Meloxicam in API, Pharmaceutical Formulations and Human Serum
AU  - Najma Sultana
AU  - Muhammad Saeed Arayne
AU  - Saeeda Nadir Ali
Y1  - 2013/04/02
PY  - 2013
N1  - https://doi.org/10.11648/j.ajac.20130101.11
DO  - 10.11648/j.ajac.20130101.11
T2  - American Journal of Applied Chemistry
JF  - American Journal of Applied Chemistry
JO  - American Journal of Applied Chemistry
SP  - 1
EP  - 8
PB  - Science Publishing Group
SN  - 2330-8745
UR  - https://doi.org/10.11648/j.ajac.20130101.11
AB  - The aim of the present work was to develop a sensitive liquid chromatographic method for the quantitation of pravastatin and diltiazem along with naproxen and meloxicam using ultraviolet detector. The separation of components was achieved on Purospher Star, C18 (5 µm, 25 x 0.46 cm) column using methanol-water (80:20 v/v) as mobile phase and pH adjusted 3.4 with 85% o-phosphoric acid. Related parameters that may influence the enrichment efficiency of speration of drugs  such as the kind and volume of elute, sample flow rate, sample pH, and volume of the drug  samples were investi-gated. Detection was performed at ambient temperature at 220 nm by pumping the mobile phase at the flow rate 1.0 mL min-1. The experimental results indicated a good linearity (R 2 > 0.9947) over the concentration range of 0.5-20 µg mL-1 for pravastatin, naproxen and meloxicam and 0.75-24 µg mL-1 for diltiazem. The method was compared by programming the detector adjusting the wavelength with time to match the individual analyte's chromophore which enhanced sensitivity with linear range 0.25-8.0, 0.5-16, 0.4-12 and 0.2-4.0 µg mL-1 for pravastatin, diltiazem, naproxen and meloxicam respectively. The LOD values shifted down from 33, 70, 50 and 80 ng mL-1 to 15, 42, 20 and 10 ng mL-1 for pravastatin, diltiazem, na-proxen and meloxicam respectively. Validation of the method showed good precision and accuracy for the proposed method. All the results indicated that this procedure could allow the simultaneous determination of these four compounds in API, pharmaceutical formulations and serum at trace levels. The method can be successfully applied for the determination of these drugs in human serum, clinical laboratories and in pharmaceutical formulations without diode array detector and without interference of excipients or endogenous components of serum.
VL  - 1
IS  - 1
ER  -

Copy | Download